Clinical Trial Results:
AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECONDLINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
Summary
|
|
EudraCT number |
2012-004793-26 |
Trial protocol |
IT DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Mar 2023
|
First version publication date |
30 Mar 2023
|
Other versions |
|
Summary report(s) |
TAS-102-201_Summary of Results_Public |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.